JBS N.V. Class A Common Shares vs Teladoc Health Inc — how do they compare? JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B), while Teladoc Health Inc trades at $5.79 (market cap $1.09B). The key difference: JBS N.V. Class A Common Shares is far larger — about 12.7× Teladoc Health Inc's market cap, and JBS N.V. Class A Common Shares pays a 10.38% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Teladoc Health Inc for 39 Days on average.
| JBS | TDOC | |
|---|---|---|
Market Cap | $13.86B | $1.09B |
Volume | 4,980,049 | 4,279,268 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $9.72 |
52-Week Low | $10.86 | $4.47 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $34.83B | $1.35B |
Dividend Yield | 10.38% | — |
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Teladoc Health (TDOC) trades at $5.81, down 1.86% on the day, with a bearish technical signal and mixed quarterly earnings performance. The company maintains strong gross margins at 68.97% but continues to report net losses, with a -7.13% net income margin for 2025. Recent developments include new executive appointments and ongoing legal investigations, while analyst consensus shows 35.71% buy ratings with a $8.83 price target.
TDOC presents a turnaround opportunity with attractive valuation metrics (P/S 0.43, EV/EBITDA 6.28) and positive cash flow from operations, but faces significant execution risks from persistent losses, BetterHelp segment challenges, and legal scrutiny. The stock trades near multi-year lows, offering potential upside if management can stabilize the business and return to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →